Confo therapeutics, a leader in drug discovery that targets G protein-coupled receptors (GPCRs), announced today that its Scientific Founder and Chair of the Scientific Advisory Board, Professor Jan Steyaert, PhD, is a recipient of the Jacob and Louise Gabbay award was selected. The award, administered by Brandeis University in Boston, is presented each year to academic, medical or industrial scientists whose research represents outstanding scientific content and significant practical applications in the biomedical sciences. Professor Steyaert is the 24thth Scientist to receive the prize and the first Belgian prizewinner. The award recognizes his contributions to the development of Camelid single domain antibodies. The translational nature of his work in the biomedical sciences enabled the creation of Confo and its ConfoBody® technology and the discovery of the company’s proprietary pipeline.
“Jan Steyaert is credited for introducing single-domain antibody technology as an exquisite tool to encapsulate inherently unstable, dynamic proteins into single functional conformations. His work is important not only for mechanisms in structural biology, but also for structure-based drug discovery in this context of the pharmaceutical industry,” said Dagmar Ringe, PhD, Chair of the Awards Committee and Harold and Bernice Davis Professor Emeritus of Aging and Neurodegenerative Diseases at Brandeis University.
“We congratulate Jan on the award and the well-deserved recognition for his pioneering work,” said Cedric Ververken, CEO of Confo Therapeutics. “We continue to benefit from his discoveries and invaluable scientific input as we continue to optimize our technology and expand our pipeline.”
‘It is an honor to receive this prestigious award, which illustrates the global impact that basic research discoveries can have on the biotech industry,’ added Professor Steyaert.
Co-founded by Professor Steyaert, Confo Therapeutics utilizes the Confo…
